NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing Well Tolerated Without Need for Supportive Care Beam on Track to Initiate Phase 1-enabling Studies by End of 2024 Beam to Host Investor Event on Dec. 8, 2024, at 8 p.m. PT SAN DIEGO, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision...
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels Multiple Myeloma Arm Demonstrated Well-Tolerated Safety Profile; On-Target Neutropenia Was Manageable With Low Rates of Febrile Neutropenia and Infections; No Treatment Emergent Adverse Events Leading to Dose Reduction In Non-Hodgkin’s Lymphoma, Cemsidomide...
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with median duration of response and median PFS not yet reached Top-line data from APEX Part 2 on-track for mid-2025 Cogent to host investor webcast on Monday, December 9 at 8:00 a.m. ET WALTHAM, Mass. and BOULDER, Colo., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a...
The combination of acimtamig with AlloNK ® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatments The combination showed a well-manageable safety profile with no unexpected safety signals MANNHEIM, Germany, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients...
MP0533 phase 1/2a dose escalation study continues with overall acceptable safety profile to date as well as initial antileukemic and pharmacodynamic activity Clinical protocol amendment in process with optimized dosing scheme to overcome target-mediated drug disposition and test the full potential of MP0533 Switch-DARPin MP0621 demonstrates intended mechanism in vivo, achieving killing of cKit+ cells while reducing off-target effects seen with systemic anti-CD47 blockade ZURICH-SCHLIEREN,...
Media Release COPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE ® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following treatment...
Media Release COPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment with epcoritamab plus lenalidomide + rituximab (R 2 ) Long-term follow-up results demonstrated strong and durable efficacy, with an estimated two-year overall survival (OS) rate of 90 percent Results follow recent...
New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10 -6 provides more accurate assessment of treatment responses SEATTLE, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new...
Admirals Group AS has entered into an agreement to sell its wholly owned subsidiary, Admirals AU PTY Ltd (Australia), a licensed investment company, to a non-related party, as part of the Admirals group’s ongoing optimization of its geographic focus. The transaction, subject to customary closing conditions, is expected to positively contribute to Admirals Group AS’s net profit and streamline its operations in alignment with its core strategy. This strategic move underscores Admirals Group...
De resultaten van de lopende fase 1/2 ATALANTA-1 studie in een zwaar voorbehandelde R/R NHL patiëntenpopulatie tonen hoge anti-tumoractiviteit en een bemoedigend veiligheidsprofiel in alle onderzochte NHL-subtypes. 96% van de patiënten kregen een infusie met verse, fitte, stem-like , early memory CD19 CAR T-celtherapie met een mediane vein-to-vein tijd van zeven dagen, waardoor cryopreservatie en overbruggingstherapie niet nodig waren. Deze resultaten ondersteunen het potentieel van Galapagos'...
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66 th American Society of Hematology (ASH) Annual Meeting...
All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Post-BEAM-101 Treatment Initial Safety Profile Consistent with Busulfan Conditioning and Autologous Hematopoietic Stem Cell Transplantation All Seven Patients Dosed Achieved Target Cell Dose with One or Two Mobilization Cycles and Experienced Rapid Neutrophil and Platelet Engraftment Markers of Hemolysis Normalized or Improved in All Patients Beam...
ASH : le rilzabrutinib a apporté un bénéfice significatif aux patients atteints de TPI dans le cadre de la première étude de phase III positive consacrée à un inhibiteur de la BTK Les données pivots de phase III montrent une réponse plaquettaire rapide et durable, une diminution des saignements, du recours à un traitement d’urgence et de la fatigue physique, ainsi qu’une amélioration des scores de qualité de vie chez les patients porteurs d’une TPI persistante ou chronique. Ces...
Hamilton, Bermuda. December 7, 2024. Avance Gas Holding Ltd. («Avance Gas» or «Company») (OSE: AGAS) refers to the announcement on August 15, 2024, regarding the sale of its VLGC fleet to BW LPG Ltd ("BW LPG" or "Buyer") for $1,050 million. Today Avance Gas announces the seventh VLGC delivery, the 2015-built vessel Pampero. In connection with the delivery, 1.350 million shares in BW LPG were issued by the Buyer to Avance Gas. The ship mortgage has been repaid and Avance Gas expects to...
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on behalf of the Sprott Physical Uranium Trust (TSX: U.UN) (TSX: U.U) (the “Trust” or “SPUT”), a closed-ended trust created to invest and hold substantially all of its assets in physical uranium, today announced that it has added additional sales agents to its at-the-market equity program (the “ATM Program”) to issue up to US$1.0 billion of units of the...
GrazieGrafico
NotizieGlobeNewsWire ha pubblicato una nuova notizia.
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on behalf of the Sprott Physical Silver Trust (NYSE: PSLV) (TSX: PSLV / PSLV.U) (the “Trust”), a closed-ended mutual fund trust created to invest and hold substantially all of its assets in physical silver bullion, today announced that it has added additional sales agents to its at-the-market equity program to issue up to US$1 billion of units of the Trust...
Grazie
NotizieGlobeNewsWire ha pubblicato una nuova notizia.
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on behalf of the Sprott Physical Gold Trust (NYSE: PHYS) (TSX: PHYS / PHYS.U) (the “Trust”), a closed-ended mutual fund trust created to invest and hold substantially all of its assets in physical gold bullion, today announced that it has added additional sales agents to its at-the-market equity program to issue up to US$1 billion of units of the Trust...
Grazie
NotizieGlobeNewsWire ha pubblicato una nuova notizia.
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on behalf of the Sprott Physical Gold and Silver Trust (NYSE: CEF) (TSX: CEF) (TSX: CEF.U) (the “Trust”), a closed-ended mutual fund trust created to invest and hold substantially all of its assets in physical gold and silver bullion, today announced that it has added additional sales agents to its at-the-market equity program to issue up to US$250 million of...
TORONTO and TAMPA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Voxtur Analytics Corp. ( TSXV: VXTR; OTCQB: VXTRF ) ("Voxtur" or the "Company"), a North American technology company creating a more transparent and accessible real estate lending ecosystem, today announced that, subsequent to the Company filing on November 28, 2024, certain disclosures were identified that require amendments to its Unaudited Condensed Interim Consolidated Financial Statements (“Financial Statements”) and the related...
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association’s 35 th International Symposium on ALS/MND, taking place Dec. 6-8, 2024, in Montreal, Canada. “The...
Grazie
Grafico
Grazie
Grafico
